• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,345.99
  • 0.84 %
  • $319.89
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Celularity Inc. (CELUW) Stock Price, News & Analysis

Celularity Inc. (CELUW) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.02

-$0

(8.21%)

Day's range
$0.02
Day's range
$0.02
50-day range
$0.0075
Day's range
$0.05
  • Country: US
  • ISIN: US1511901134
52 wk range
$0.02
Day's range
$0.02
  • CEO: Dr. Robert Joseph Hariri M.D., Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -11.52
  • Piotroski Score 5.00
  • Grade Underweight
  • Symbol (CELUW)
  • Company Celularity Inc.
  • Price $0.02
  • Changes Percentage (8.21%)
  • Change -$0
  • Day Low $0.02
  • Day High $0.02
  • Year High $0.02

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/30/2023
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.87
  • Trailing P/E Ratio -0.03
  • Forward P/E Ratio -0.03
  • P/E Growth -0.03
  • Net Income $-196,295,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Celularity Inc. Frequently Asked Questions

  • What is the Celularity Inc. stock price today?

    Today's price of Celularity Inc. is $0.02 — it has decreased by 8.21% in the past 24 hours. Watch Celularity Inc. stock price performance more closely on the chart.

  • Does Celularity Inc. release reports?

    Yes, you can track Celularity Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Celularity Inc. stock forecast?

    Watch the Celularity Inc. chart and read a more detailed Celularity Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Celularity Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Celularity Inc. stock ticker.

  • How to buy Celularity Inc. stocks?

    Like other stocks, CELUW shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Celularity Inc.'s EBITDA?

    Celularity Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Celularity Inc.’s financial statements.

  • What is the Celularity Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -8.6203943612, which equates to approximately -862.04%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Celularity Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Celularity Inc.'s financials relevant news, and technical analysis. Celularity Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Celularity Inc. stock currently indicates a “sell” signal. For more insights, review Celularity Inc.’s technical analysis.

  • A revenue figure for Celularity Inc. for its last quarter?

    Celularity Inc. published it's last quarterly revenues at $12.11 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.